Current and newer agents for hypertensive emergencies

Current Hypertension Reports

Volumn 16, Issue 7, 2014, Pages

  Padilla Ramos, Alan ^a,e   Varon, Joseph ^b,c,d,e,f  

^a UNIVERSIDAD AUTÓNOMA DE BAJA CALIFORNIA   (Mexico)

^b University General Hospital   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^e Dorrington Medical Associates   (United States)

^f NONE   (United States)

Author keywords

Blood pressure control; Clevidipine; Clinical trials; Hypertension; Hypertensive crisis; Hypertensive emergency; Hypertensive urgency; Labetalol; Nicardipine

Indexed keywords

ANTIHYPERTENSIVE AGENT; CLEVIDIPINE; ENALAPRILAT; ESMOLOL; FENOLDOPAM; GLYCERYL TRINITRATE; HYDRALAZINE; LABETALOL; NICARDIPINE; NIFEDIPINE; NITROPRUSSIDE SODIUM; PHENTOLAMINE;

ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL FEATURE; DRUG CHOICE; EMERGENCY TREATMENT; EVIDENCE BASED PRACTICE; HUMAN; HYPERTENSION; HYPERTENSIVE CRISIS; MORBIDITY; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; EMERGENCY; PHYSIOLOGY; PROCEDURES;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; CLINICAL TRIALS AS TOPIC; EMERGENCIES; HUMANS; HYPERTENSION;

EID: 84901582843     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-014-0450-z     Document Type: Article

References (84)

1. Cutler JA, Sorlie PD, Wolz M, Thom T, Fields LE, Roccella EJ. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988-1994 and 1999-2004. Hypertension. 2008;52(5):818-27.
2. Vital signs: prevalence, treatment, and control of hypertension-United States, 1999-2002 and 2005-2008. Morb Mortal Wkly Rep. 2011;60(4):103-8.
3. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000.JAMA. 2003;290(2):199-206. (Pubitemid 37430058)
4. Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics - 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117(4):e25-e146.
5. Whitworth JA. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens. 2003;21(11):1983-92. (Pubitemid 38296854)
6. Volhard F. Die Brightsche Nierenkrankheit: Springer; 1914.
7. Keith NM, Wagener HP, Barker NW. Some different types of essential hypertension: their course and prognosis. Am J Med Sci. 1974;268(6):336-45.
8. Lenfant C, Chobanian AV, Jones DW, Roccella EJ. Seventh report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7): resetting the hypertension sails. Hypertension. 2003;41(6):1178-9. (Pubitemid 36706061)
9. James PA, Oparil S, Carter BL, et al. evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507-20. This latest report of the JNC offers classes of medications that can be used for BP control. Although this review does not adress the hypertensive crisis, it is one of the most important references in the United States and throughout the world for treating this pathology.
10. Varon J, Marik PE. The diagnosis and management of hypertensive crises. Chest. 2000;118(1):214-27. (Pubitemid 30485512)
11. Varon J. Treatment of acute severe hypertension: current and newer agents. Drugs. 2008;68(3):283-97. (Pubitemid 351225810)
12. Varon J. Diagnosis andmanagement of labile blood pressure during acute cerebrovascular accidents and other hypertensive crises. Am J Emerg Med. 2007;25(8):949-59. (Pubitemid 47505390)
13. Schiller JS, Lucas JW, Ward BW, Peregoy JA. Summary health statistics for U.S. adults: National Health Interview Survey, 2010. Vital and health statistics Series 10, Data from the National Health Survey. 2012(252):1-207
14. Prisant LM, Carr AA, Hawkins DW. Treating hypertensive emergencies. Controlled reduction of blood pressure and protection of target organs. Postgrad Med. 1993;93(2):92-6. 101-4, 8-10.
15. Marik PE, Varon J. Hypertensive crises: challenges and management. Chest. 2007;131(6):1949-62. (Pubitemid 46981658)
16. Varon J, Marik P. Clinical review: the management of hypertensive crises. Crit Care. 2003;7(5):374-84. (Pubitemid 37236308)
17. AultMJ, Ellrodt AG. Pathophysiological events leading to the endorgan effects of acute hypertension. Am J Emerg Med. 1985;3(6 Suppl):10-5. (Pubitemid 16135312)
18. Wallach R, Karp RB, Reves JG, Oparil S, Smith LR, James TN. Pathogenesis of paroxysmal hypertension developing during and after coronary bypass surgery: a study of hemodynamic and humoral factors. Am J Cardiol. 1980;46(4):559-65. (Pubitemid 10009807)
19. Han Y, RungeMS, Brasier AR. Angiotensin II induces interleukin-6 transcription in vascular smooth muscle cells through pleiotropic activation of nuclear factor-kappa B transcription factors. Circ Res. 1999;84(6):695-703. (Pubitemid 29157337)
20. Zampaglione B, Pascale C, Marchisio M, Cavallo-Perin P. Hypertensive urgencies and emergencies. Prevalence and clinical presentation. Hypertension. 1996;27(1):144-7. (Pubitemid 26017693)
21. Garcia Jr JY, Vidt DG. Current management of hypertensive emergencies. Drugs. 1987;34(2):263-78.
22. Finnerty Jr FA. Management of hypertensive encephalopathy. Herz. 1978;3(5):300-4.
23. Chen K, Varon J, Wenker OC, Judge DK, Fromm Jr RE, Sternbach GL. Acute thoracic aortic dissection: the basics. J Emerg Med. 1997;15(6):859-67. (Pubitemid 27524584)
24. Khan IA, Nair CK. Clinical, diagnostic, and management perspectives of aortic dissection. Chest. 2002;122(1):311-28. (Pubitemid 34754180)
25. Estrera AL, Miller 3rd CC, Safi HJ, et al. Outcomes of medical management of acute type B aortic dissection. Circulation. 2006;114(1 Suppl):I384-9. (Pubitemid 44297180)
26. Vaughan CJ, Delanty N. Hypertensive emergencies. Lancet. 2000;356(9227):411-7. (Pubitemid 30487503)
27. Gandhi SK, Powers JC, Nomeir AM, et al. The pathogenesis of acute pulmonary edema associated with hypertension. N Engl J Med. 2001;344(1):17-22. (Pubitemid 32064840)
28. Weder AB, Erickson S. Treatment of hypertension in the inpatient setting: use of intravenous labetalol and hydralazine. J Clin Hypertens. 2010;12(1):29-33.
29. Fontes ML, Varon J. Perioperative hypertensive crisis: newer concepts. Int Anesthesiol Clin. 2012;50(2):40-58. Over 72 million of Americans have hypertension. Of the patients that present to noncardiac surgery one third are hypertensive. The consequences of hypertension are been associated with multiple target-organ complications. This article provides an overview of hypertensive crises.
30. Varon J, Marik PE. Perioperative hypertension management. Vasc Health Risk. 2008;4(3):615-27. (Pubitemid 352037919)
31. .• Anderson CS, Heeley E, Huang Y, et al. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med. 2013;368(25):2355-65. This study randomly assigned patients with spontaneous intracerebral hemorrhage to receive therapy to lower systolic blood pressure to either <180mmHg (guideline-recommended) or <140mmHg. Subjects demostrated improved functional outcomes with intensive SBP lowering treatment.
32. .• Hill MD, Muir KW. INTERACT-2: should blood pressure be aggressively lowered acutely after intracerebral hemorrhage? Stroke. 2013;44(10):2951-2. This study randomly assigned patients with spontaneous intracerebral hemorrhage to receive therapy to lower systolic blood pressure to either <180mmHg (guideline-recommended) or <140mmHg. They demostrated that <140mmHg is a safe target and suggested that additional data is required to recommend this practice.
33. .• Sarafidis PA, Georgianos PI, Malindretos P, Liakopoulos V. Pharmacological management of hypertensive emergencies and urgencies: focus on newer agents. Expert Opin Investig Drugs. 2012;21(8):1089-106. In this review the author suggests the use of less toxic hypertensive agents like nicardipine, fenoldopam, labetalol and esmolol over older agents such as nitroprusside, nitroglycerin and hydralaizne.
34. Schirger A, Spittell Jr JA. Pharmacology and clinical use of hydralazine in the treatment of diastolic hypertension. Am J Cardiol. 1962;9:854-9.
35. Cogan JJ, Humphreys MH, Carlson CJ, Rapaport E. Renal effects of nitroprusside and hydralazine in patients with congestive heart failure. Circulation. 1980;61(2):316-23. (Pubitemid 10214989)
36. Magee LA, Cham C, Waterman EJ, Ohlsson A, von Dadelszen P. Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. BMJ. 2003;327(7421):955-60. (Pubitemid 37330398)
37. Tumlin JA, Dunbar LM, Oparil S, et al. Fenoldopam, a dopamine agonist, for hypertensive emergency: a multicenter randomized trial. Fenoldopam Study Group. Acad Emerg Med. 2000;7(6):653-62. (Pubitemid 30390491)
38. Elliott WJ, Weber RR, Nelson KS, et al. Renal and hemodynamic effects of intravenous fenoldopam versus nitroprusside in severe hypertension. Circulation. 1990;81(3):970-7. (Pubitemid 20090395)
39. Reisin E, Huth MM, Nguyen BP, Weed SG, Gonzalez FM. Intravenous fenoldopam versus sodium nitroprusside in patients with severe hypertension. Hypertension. 1990;15(2 Suppl):I59-62.
40. Duprez D. Arterial Hypertension. In: Toth PP, Cannon CP, editors. Comprehensive Cardiovascular Medicine in the Primary Care Setting: Humana Press; 2011. p. 25-58.
41. Friederich JA, Butterworth JF. Sodium nitroprusside: twenty years and counting. Anesth Analg. 1995;81(1):152-62.
42. Cohn JN, Franciosa JA, Francis GS, et al. Effect of short-term infusion of sodium nitroprusside on mortality rate in acute myocardial infarction complicated by left ventricular failure: results of a Veterans Administration cooperative study. N Engl J Med. 1982;306(19):1129-35. (Pubitemid 12161335)
43. Mann T, Cohn PF, Holman LB, Green LH, Markis JE, Phillips DA. Effect of nitroprusside on regional myocardial blood flow in coronary artery disease. Results in 25 patients and comparison with nitroglycerin. Circulation. 1978;57(4):732-8. (Pubitemid 8306850)
44. Griswold WR, Reznik V, Mendoza SA. Nitroprusside-induced intracranial hypertension. JAMA. 1981;246(23):2679-80.
45. Hall VA, Guest JM. Sodium nitroprusside-induced cyanide intoxication and prevention with sodium thiosulfate prophylaxis. Am J Crit Care. 1992;1(2):19-25.
46. Parent R, Leblanc N, LavalleeM. Nitroglycerin reduces myocardial oxygen consumption during exercise despite vascular tolerance. Am J Physiol Heart Circ Physiol. 2006;290(3):H1226-34.
47. Flaherty JT, Magee PA, Gardner TL, Potter A, MacAllister NP. Comparison of intravenous nitroglycerin and sodium nitroprusside for treatment of acute hypertension developing after coronary artery bypass surgery. Circulation. 1982;65(6):1072-7. (Pubitemid 12105090)
48. Brundtland GH. From the World Health Organization. Reducing risks to health, promoting healthy life. JAMA. 2002;288(16):1974. (Pubitemid 35204682)
49. Toman J, Lupinek Z, Janousek S, Nechvatal L, Zeman K. Hemodynamic effects of transdermal nitroglycerin patches in patients with acute myocardial infarction. Cardiology. 1991;79 Suppl 2:58-62.
50. Levy JH. Treatment of perioperative hypertension. Anesthsiol Clin of N Am. 1999;17(3):567-79. (Pubitemid 29446981)
51. Munoz Alameda LE, Barcina SanchezM. [Intravenous nicardipine: a new calcium antagonist for perioperative use. Rev Esp Anestesiol Reanim. 2001;48(2):71-80. (Pubitemid 32199293)
52. Wallin JD, Cook ME, Blanski L, et al. Intravenous nicardipine for the treatment of severe hypertension.AmJMed. 1988;85(3):331-8.
53. Sorkin E, Clissold S. Nicardipine. Drugs. 1987;33(4):296-345.
54. Kross RA, Ferri E, Leung D, et al. A comparative study between a calcium channel blocker (Nicardipine) and a combined alpha-beta-blocker (Labetalol) for the control of emergence hypertension during craniotomy for tumor surgery. Anesth Analg. 2000;91(4):904-9.
55. Drozda Jr J, Messer JV, Spertus J, et al. ACCF/AHA/AMA-PCPI 2011 performance measures for adults with coronary artery disease and hypertension: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures and the American Medical Association- Physician Consortium for Performance Improvement. J Am Coll Cardiol. 2011;58(3):316-36.
56. Neutel JM, Smith DH, Wallin D, et al. A comparison of intravenous nicardipine and sodium nitroprusside in the immediate treatment of severe hypertension. Am J Hypertens. 1994;7(7 Pt 1):623-8. (Pubitemid 24265158)
57. .•• Peacock WF, Varon J, Baumann BM, et al. CLUE: a randomized comparative effectiveness trial of IV nicardipine versus labetalol use in the emergency department. Crit Care. 2011;15(3):R157. This was a multicenter randomized clnical trial with the objective of comparing IV nicardipine versus IV labetalol using doses recommended by the food and drug administration. A total of 226 patients were enrolled. Nicardipine-receiving patient reached BP goals more often than labetalol-receiving patients 30 minutes after the dose. No significant diference in adverse effects was noted.
58. Rivera A, Montoya E, Varon J. Intravenous clevidipine for management of hypertension. Integr Blood Press Control. 2010;3:105-11.
59. .•• Espina IM, Varon J. Clevidipine : a state-of-the-art antihypertensive drug under the scope. Expert Opin Pharmacother. 2012;13(3):387-93. This article analyzed the characteristics of Clevidipine including half-life, interaction, dosings and efficacy. Over 90%of patients receiving clevidipine reached target blood pressure within 30 minutes of administration.
60. Levy JH, Mancao MY, Gitter R, et al. Clevidipine effectively and rapidly controls blood pressure preoperatively in cardiac surgery patients: the results of the randomized, placebo-controlled efficacy study of clevidipine assessing its preoperative antihypertensive effect in cardiac surgery-1. Anesth Analg. 2007;105(4):918-25. (Pubitemid 47479301)
61. .• Tulman DB, Stawicki SP, Papadimos TJ, Murphy CV, Bergese SD. Advances in management of acute hypertension: a concise review. Disc Med. 2012;13(72):375-83. This review focuses on Clevdipine as an effective hypotensive agents, focusing on the pharmacodynamic and pharmacokinect properties and the saftly profile.
62. .• Mirtallo JM, Dasta JF, Kleinschmidt KC, Varon J. State of the art review: Intravenous fat emulsions: current applications, safety profile, and clinical implications. Ann Pharmacother. 2010;44(4):688-700. This review focuses on propofol and clevidipine to assess the safety profile of intravenous fat emulsions, demonstrating a low rate of lipid-related adverse effects when administrered within guideline recommendations.
63. Singla N, Warltier DC, Gandhi SD, et al. Treatment of acute postoperative hypertension in cardiac surgery patients: an efficacy study of clevidipine assessing its postoperative antihypertensive effect in cardiac surgery-2 (ESCAPE-2), a randomized, doubleblind, placebo-controlled trial. Anesth Analg. 2008;107(1):59-67.
64. .• Aronson S, Dyke CM, Stierer KA, et al. The ECLIPSE trials: comparative studies of clevidipine to nitroglycerin, sodium nitroprusside, and nicardipine for acute hypertension treatment in cardiac surgery patients. Anesth Analg. 2008;107(4):1110-21. Data from three prospective studies demostrate that there was no difference in the incidence of adverse effects between clevidipinereceiving patients compared with the other hypotensive drugs.
65. .• Peacock F, Varon J, Ebrahimi R, Dunbar L, Pollack Jr CV. Clevidipine for severe hypertension in acute heart failure: a VELOCITY trial analysis. Congest Heart Fail. 2010;16(2):55-9. In patients with acute heart failure, there were no treatment-related adverse effects, demostrating that clevidipine is a safe agent to decrease SBP in this group of patients.
66. Conner CS. Labetalol: an alpha- and beta-blocker. Drug Intell Clin Pharm. 1983;17(7-8):543-4. (Pubitemid 13068112)
67. Huey J, Thomas JP, Hendricks DR, Wehmeyer AE, Johns LJ, MacCosbe PE. Clinical evaluation of intravenous labetalol for the treatment of hypertensive urgency. Am J Hypertens. 1988;1(3 Pt 3):284s-9s.
68. Wright JT, Wilson DJ, Goodman RP, Minisi AJ. Labetalol by continuous intravenous infusion in severe hypertension. J Clin Hypertens. 1986;2(1):39-43.
69. Richards DA. Pharmacological effects of labetalol in man. Brit J Clin Pharmacol. 1976;3(4 Suppl 3):721-3.
70. .•• Cannon CM, Levy P, Baumann BM, et al. Intravenous nicardipine and labetalol use in hypertensive patients with signs or symptoms suggestive of end-organ damage in the emergency department: a subgroup analysis of the CLUE trial. BMJ open. 2013;3(3). The objective of this study was to compare IVinfusion of nicardipine vs IV bolus of labetalol to manage hypertensive emergencies. Of the 141 patients who were enrolled, 49.6% received nicardipine and 51.7% received labetalol. Patients receiving nicardipine were statisticaly more likely to reach target SBP within 30 minutes than those who received labetalol.
71. MacCarthy EP, Bloomfield SS. Labetalol: a review of its pharmacology, pharmacokinetics, clinical uses and adverse effects. Pharmacotherapy. 1983;3(4):193-219. (Pubitemid 13014328)
72. .• Shekhar S, Sharma C, Thakur S, Verma S. Oral nifedipine or intravenous labetalol for hypertensive emergency in pregnancy: a randomized controlled trial. Obstet Gynecol. 2013;122(5):1057-63. This trial pregant women with SBP >159mmHg or DPB >109mmHg received 10mg of nifedipine PO, 20,40,80mg of labetalol or IVor placebo. Nifedipinelowered blood pressure more quickly than labetalol.
73. Papadopoulos DP, Mourouzis I, Thomopoulos C, Makris T, Papademetriou V. Hypertension crisis. Blood Press. 2010;19(6):328-36.
74. .•• Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-ElevationMyocardial Infarction) developed in collaboration with theAmerican College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic EmergencyMedicine. J Am Coll Cardiol. 2007;50(7):e1-e157. This ACC/AHA Guidelines defined systolic hypertension as a predictor of adverse outcome in UA/NSTEMI, and recommend medical management and lifestyle changes.
75. Gray RJ. An ultra short-acting beta-adrenergic blocker. Chest. 1988;93(2):398-403.
76. Rosei EA, Trust PM, Brown JJ, Lever AF, Robertson JI. Letter: intravenous labetalol in severe hypertension. Lancet. 1975;2(7944):1093-4.
77. Turlapaty P, Laddu A, Murthy VS, Singh B, Lee R. Esmolol: a titratable short-acting intravenous beta blocker for acute critical care settings. Am Heart J. 1987;114(4 Pt 1):866-85. (Pubitemid 17158470)
78. Esmolol WD. A review of its therapeutic efficacy and pharmacokinetic characteristics. Clin Pharmacokinet. 1995;28(3):190-202.
79. Varon J. The diagnosis and treatment of hypertensive crises. Postgrad Med. 2009;121(1):5-13.
80. Zangrillo A, Turi S, Crescenzi G, et al. Esmolol reduces perioperative ischemia in cardiac surgery: a meta-analysis of randomized controlled studies. J Cardiothorac Vasc Anesth. 2009;23(5):625-32.
81. Ziegler MG. Advances in the acute therapy of hypertension. Crit Care Med. 1992;20(12):1630-1.
82. McMillian WD, Trombley BJ, Charash WE, Christian RC. Phentolamine continuous infusion in a patient with pheochromocytoma. Am J Health Syst Pharm. 2011;68(2):130-4.
83. Rhoney D, Peacock WF. Intravenous therapy for hypertensive emergencies, part 2. Am J Health Syst Pharm. 2009;66(16):1448-57.
84. Curry SC, Arnold-Capell P. Toxic effects of drugs used in the ICU. Nitroprusside, nitroglycerin, and angiotensin-converting enzyme inhibitors. Crit Care Clin. 1991;7(3):555-81.